Gabapentin Capsule
Product Images NDC 60760-814

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-814). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin (Gabapentin 60760 814 90)

Gabapentin Capsules, USP 300 mg oral capsules packaging label displays 90 count. The label lists the NDC 60760-814-90 with placeholders for lot and expiration dates. Manufactured by Slides Pharma Science Limited, India, and packaged by St Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes directions to use as directed and store at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A pharmacokinetic formula panel showing the equation for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor of 0.85 for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin, showing a cyclohexane ring bonded to two side chains: one with an amino group (CH2NH2) and one with a carboxyl group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis is labeled 'Weeks' from Baseline to 8, and the y-axis shows 'Mean Pain Score' from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain score with Gabapentin compared to placebo.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Line graph showing mean pain scores over 7 weeks for placebo and Gabapentin at daily doses of 1800 mg and 2400 mg. The x-axis represents weeks including a 3-week dose titration and a 4-week fixed dose period, and the y-axis represents mean pain score. Gabapentin groups show a decline in pain scores compared to placebo over time.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing response rates in two studies. It shows percentages for placebo (PBO) and different doses of Gabapentin (GBP) with GBP 3600, 1800, and 2400 mg categories, indicating higher response rates for Gabapentin than placebo in both Study 1 and Study 2.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot chart showing the relationship between daily dose in mg (x-axis) and difference percentage (y-axis) for Gabapentin. The chart compares results from three studies labeled a, b, and c, with data points presented at daily doses of approximately 600, 900, 1200, and 1800 mg. Percent difference ranges from around 5% to 18%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.